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Introduction. The present study aimed to assess the metabolic syndrome among postmenopausal women in Gorgan, Iran. Materials
and Methods. The study was conducted on hundred postmenopausal women who were referred to the health centers in Gorgan.
Metabolic syndrome was diagnosed using Adult Treatment Panel III (ATP III) guidelines. Results. Themean bodymass index, waist
circumference, hip, circumference waist-to-hip ratio, diastolic blood pressure, and triglyceride and fasting blood glucose levels
were significantly high among postmenopausal women with metabolic syndrome, but the mean HDL-cholesterol was significantly
low (P < 0.05). Overall prevalence of metabolic syndrome was 31%. Body mass index and waist circumference had a positive
correlation with a number of metabolic syndrome factors (P < 0.001). Body mass index, waist circumference, and waist-to-hip
ratio had a positive correlation with each other (P < 0.001). BMI had relatively high correlation with WC (P < 0.001). Conclusions.
Our results show that postmenopausal status might be a predictor of metabolic syndrome. Low HDL-cholesterol level and high
abdominal obesity are the most frequent characteristics in comparison to other metabolic components. Our study also showed
some related factors of metabolic syndrome among postmenopausal women. These factors may increase cardiovascular risk among
postmenopausal women with metabolic syndrome.
1. Introduction
The metabolic syndrome (MetS) is described by the clus-
tering of several risk factors for cardiovascular disease
(CVD) such as hypertension, dyslipidaemia, obesity (partic-
ularly central obesity), insulin resistance, and high fasting
plasma glucose [1]. In 2001, The Third Report of National
Cholesterol Education Program Expert Panel on Detection,
Evaluation, and Treatment of High Blood Cholesterol in
Adults (Adult Treatment Panel III) (ATP III) emphasized
the importance of the metabolic syndrome and provided
a working definition of this syndrome for the first time
[2]. Some studies showed the prevalence of metabolic syn-
drome among postmenopausal women in China, India, and
Brazil to be 33.5%, 55%, and 34.7%, respectively [3–5].
Diﬀerences in genetic background, diet, levels of physical
activity, age and sex structure all influence the prevalence
of both metabolic syndrome and its components [6].
Cardiovascular disease is one of the main reasons of death
among women in the world [7]. The studies indicated that
women aged more than 55 have a higher incidence of
cardiovascular disease than younger women [8–10]. Other
studies showed that there is a high prevalence of metabolic
syndrome among postmenopausal women, which varies
from 32.6% to 41.5% [11–13]. Study of Rossi et al. [14]
demonstrated that postmenopausal women with metabolic
syndrome have lower incidence of cardiovascular risk factors.
The mechanism behind the role of menopausal risk factors
in initiating cardiovascular disease remains unclear [15].
Some studies have shown that there is no diﬀerence in
cardiovascular risk factors when comparing premenopausal
with postmenopausal women [15–18]. In several studies, the
incidences of metabolic syndrome among postmenopausal
women were found to be increased in the world [19, 20].
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Some other studies showed that there is an elevation in
systolic blood pressure [21], serum total cholesterol, and
triglycerides [22] and a reduction in HDL-cholesterol levels
[23] among postmenopausal women. Studies in Iran showed
that prevalence of the metabolic syndrome was 35–58%
[24, 25]. There is no data on the prevalence of metabolic
syndrome among postmenopausal women in Gorgan (South
East of Caspian Sea), Iran. Therefore, it is very important to
set up a study on the postmenopausal women with a risk of
metabolic syndrome. The present study aimed to assess the
metabolic syndrome among postmenopausal women in this
area.
2. Subjects andMethods
This cross-sectional study was performed in the Biochem-
istry and Metabolic Disorders Research Center of Gorgan,
Golestan province (South East of Caspian Sea, North East
of Iran) in 2011. The study was conducted on hundred
postmenopausal women who were referred to the diﬀerent
health centers in Gorgan. Postmenopausal women who
had at least 1-year history of cessation of menses were
included. All the included subjects provided an informed
consent. At the point of study entry, all study participants
were subjected to clinical and biochemical investigations.
Data were collected by trained interviewers. First of all, a
questionnaire was completed at each health center by trained
interviewers. Demographic information is achieved by a
questionnaire. The exclusion criterion was the coexistence
of any other serious illness; this included having hormone
replacement therapy, taking drugs such as antidiabetes
and antihypertensive antilipidemic, agents and smokers. A
venous blood sample was collected from all the subjects who
came after 8–12 hours in the morning after an overnight fast.
The samples were centrifuged for 10 minutes at 3000 rpm.
The serum was used for estimating fasting blood glucose,
triglycerides, total cholesterol, LDL-cholesterol, and HDL-
cholesterol concentrations, by biochemical kit using spec-
trophotometer techniques (Model JENWAY 6105 UV/VIS)
in the Biochemistry and Metabolic Disorders Research
Center (School of Medicine). Postmenopausal women were
considered to have metabolic syndrome if they had any three
or more of the following, according to the ATP III Criteria:
[2]
(A) abdominal obesity: waist Circumference >88 cm,
(B) hypertriglyceridaemia: serum triglycerides level
>150mg/dL,
(C) low HDL-cholesterol: <50mg/dL,
(D) high blood pressure: SBP > 130mmHg and/or DBP
> 85mmHg or on treatment for hypertension,
(E) high fasting glucose: serum glucose level > 110mg/dL
or on treatment for diabetes.
Weight was then measured, while subjects were min-
imally clothed without shoes, using digital scales. Height
was measured in standing position without shoes using tape
meter while the shoulder was in a normal position. Body
mass index (BMI) was calculated as weight in kilograms
divided by height in meters squared. Those with a BMI of
25.0–29.9 Kg/m2 were classified as overweight, whilst those
with a BMI ≥ 30Kg/m2 were defined as obese. Subjects
with BMI greater than 45Kg/m2 were considered very obese
[26]. Waist circumference was measured at the point halfway
between the lower border of ribs and the iliac crest in a
horizontal plane [27], and hip circumference was measured
at the widest level over the greater trochanters. Waist-to-
hip ratio was calculated as waist circumference divided
by hip circumference. Systolic and diastolic blood pressure
was measured twice after 10–15 minutes resting in sitting
position from the right hand. Two measurements were done
all postmenopausal women at five-minute intervals and we
used the average of the 2 measurements. The results were
reported as percentages and mean ± SD. The statistical
analysis was done with SPSS-16 version software. The results
were evaluated by using Student T-test and logistic regression
analysis. Statistical significance was considered at P < 0.05.
3. Results
A total of hundred postmenopausal women were studied.
Table 1 shows the baseline data of postmenopausal women
with and without metabolic syndrome. The mean age of
subjects was 54.12 ± 5.28 years, and the mean number of
years since menopause was 5.22 ± 3.40. The mean body
mass index, waist circumference, hip, waist-to-hip ratio,
diastolic blood pressure, and triglyceride and fasting blood
glucose levels were significantly high among postmenopausal
women with metabolic syndrome, but the mean HDL-
cholesterol was low (P < 0.05). There were no significant
diﬀerences in the age, years since menopause, total choles-
terol, systolic blood pressure, and LDL-cholesterol of post-
menopausal women with and without metabolic syndrome.
Table 2 shows the prevalence and component of metabolic
syndrome among postmenopausal women with metabolic
syndrome. Overall prevalence of the metabolic syndrome
among postmenopausal women was 31%. The percentages
of fasting blood sugar >110mg/dL, high density lipoprotein-
cholesterol < 50mg/dL, Triglyceride > 150mg/dL, waist
circumference > 88 cm, and systolic blood pressure >
130mmHg/diastolic blood pressure > 85mmHg are pre-
sented in Table 2. The percentages of these components of
metabolic syndrome among postmenopausal women were
17, 30, 16, 29, and 16%, respectively. Table 3 shows the
correlation between the number of metabolic syndrome
factors and body mass index, waist circumference, and waist-
to-hip ratio. Linear regression analysis shows that body mass
index and waist circumference had a positive correlation with
the number of metabolic syndrome factors (P < 0.001). BMI
had relatively higher correlation with number of metabolic
syndrome factors (P < 0.001). Table 4 shows the correlation
between body mass index, waist circumference, and waist-
to-hip ratio. The pearson correlation analysis shows that
all indices had a positive correlation with each other (P <
0.001). BMI had relatively high correlation with WC (P <
0.001).
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Table 1: Baseline data of postmenopausal women (total subjects and subjects with and without metabolic syndrome).
Parameters
Total number of
postmenopausal women
Postmenopausal women with
metabolic syndrome
Postmenopausal women without
metabolic syndrome
P value
All women, no. (%) 100 31 69
Age (years) 54.32 ± 5.26 54.51 ± 5.31 54.31 ± 5.39 0.865
Years since menopause 5.36 ± 3.38 5.0 ± 3.54 5.62 ± 3.37 0.403
BMI, kg/m2 30.98 ± 5.52 33.68 ± 5.40 29.77 ± 5.17 0.001
WC, cm 91.12 ± 11.70 97.98 ± 9.47 88.04 ± 11.34 <0.001
Hip circumference, cm 104.61 ± 9.23 109.03 ± 10.43 102.62 ± 7.95 0.001
WHR 0.87 ± 0.09 0.89 ± 0.07 0.84 ± 0.13 0.030
SBP, mmHg 150.23 ± 17.02 160.0 ± 20.45 135.32 ± 1.83 0.505
DBP, mmHg 78.72 ± 1.24 83.61 ± 1.10 76.52 ± 1.25 0.008
FBS, mg/dL 107.66 ± 63.53 143.45 ± 100.38 91.57 ± 24.17 0.008
TG, mg/dL 122.94 ± 91.67 171.90 ± 124.20 100.94 ± 62.0 <0.001
T-Chol, mg/dL 210.87 ± 49.28 219.71 ± 49.80 206.90 ± 48.88 0.231
HDL-Chol, mg/dL 46.49 ± 14.23 42.54 ± 8.60 48.26 ± 15.86 0.022
LDL-Chol, mg/dL 129.32 ± 40.52 128.32 ± 44.23 129.77 ± 39.07 0.870
BMI: body mass index, WC: waist circumference, WHR: waist-to-hip ratio, SBP: systolic blood pressure, DBP: diastolic blood pressure, FBS: fasting blood
glucose, TG: triglyceride, T-CHOL: total cholesterol, HDL-CHOL: HDL-cholesterol, and LDL-CHOL: LDL-cholesterol.
Table 2: Prevalence of metabolic syndrome and the components of
metabolic syndrome in postmenopausal women.
Number %
Metabolic syndrome 31 31
Fasting blood sugar > 110mg/dL 17 17
High-density lipoprotein-cholesterol < 50mg/dL 30 30
Triglyceride > 150mg/dL 16 16
Waist circumference > 88 cm 29 29
Systolic blood pressure > 130mmHg/diastolic blood
pressure > 85mmHg
16 16
Table 3: Regression analysis of number of the metabolic syndrome
factors versus BMI, WC, and WHR.
BMI WC WHR
R 0.511 0.406 0.213
R2 0.261 0.165 0.045
Coeﬃcient 0.053 0.024 1.667
Constant 1.623 1.039 1.926
P 0.003 0.024 0.251
BMI: body mass index, WC: waist circumference, and WHR: waist-to-hip
ratio.
4. Discussion
In our study, we found that the mean body mass index,
waist circumference, hip circumference, waist-to-hip ratio,
diastolic blood pressure, and triglyceride and fasting blood
glucose levels were significantly high among postmenopausal
Table 4: Correlation between the anthropometric indices in post-
menopausal women.
BMI WC WHR
BMI — 0.807∗ 0.363∗
WC 0.807∗ — 0.742∗
WHR 0.363∗ 0.742∗ —
∗P < 0.001.
women with metabolic syndrome, but the mean HDL-
cholesterol was low. Many studies address the relation of
menopause with blood pressure. The study of Bengtsson
showed that there is a little reduction in systolic blood
pressure after menopause [28]. Some other studies showed
that blood pressure is not changed with menopausal status
[29]. It has been shown that there is an elevation in systolic
blood pressure among postmenopausal women without
any change in diastolic blood pressure [30]. Our study
shows that systolic and diastolic blood pressure was high
among postmenopausal women with metabolic syndrome.
Our study also shows that diastolic blood pressure was
significantly high among postmenopausal women with
metabolic syndrome. This may suggest that diastolic blood
pressure is one of the risk factors for cardiovascular disease
among postmenopausal women with metabolic syndrome.
Our study shows that triglycerides were significantly high
among postmenopausal women with metabolic syndrome.
There are diﬀerent studies about the menopausal eﬀect
on triglycerides. Some studies showed no eﬀect [15, 31,
32] while other studies showed elevations of triglyceride
levels after menopause [23, 33, 34]. Our finding shows
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low HDL-cholesterol level among postmenopausal women
with metabolic syndrome. There are some studies showing
reduction and elevation of HDL-cholesterol levels following
menopause [23, 35]. Most studies have shown that plasma
HDL-C levels either fall slightly [36–38] or remain stable
[16] with menopause. Some studies show increasing of plas-
ma HDL-C levels after menopause in Korean and Iranian
population [39, 40]. The study of Kreisberg showed that
reductions in HDL-cholesterol should be taken into account
as one of coronary heart disease risk factors among post-
menopausal women [41]. It has been shown that there is
an increase in fasting blood sugar among postmenopausal
women with metabolic syndrome [42]. Our results showed
a significant increase in fasting blood sugar between post-
menopausal women with and without metabolic syndrome.
Waist circumference was elevated among postmenopausal
women with metabolic syndrome. It was also shown that
postmenopausal women were overweight and obese. Body
mass index and waist circumference have shown to have
positive correlation with the number of metabolic syndrome
factors, and also body mass index, waist circumference
and waist-to-hip ratio had a positive correlation with each
other. The study of Lobo showed that weight increase and
obesity greatly increase prevalence of metabolic syndrome
among postmenopausal women. Changes in central obesity
can cause metabolism abnormality and influence health
[43]. Estrogen secretion is decreased among postmenopausal
women depending on metabolic alterations and resulting
agglomeration of abdominal fat. It is important to reduce
the risk of cardiovascular disease among postmenopausal
women. It suggests that among postmenopausal women
blood glucose, blood pressure, lipid profile monitoring
and changing their life style can lead to weight loss by
diet and sport [44]. The prevalence of metabolic syn-
drome among postmenopausal women is 31%. The study
on postmenopausal women in Austria showed that the
prevalence of metabolic syndrome was 32.6% [45] which
was similar to that in our finding. In another study on
postmenopausal women in Chengdu, China, the prevalence
of metabolic syndrome was shown to be 37.34%, which was
higher than our finding [12]. In our study, we found high
prevalence of the components of metabolic syndrome among
postmenopausal women. Low HDL-cholesterol and high
waist circumference were the most usual factors of metabolic
abnormality among postmenopausal women. Prevalence
of cardiovascular diseases might be increased. This may
happen with high prevalence of metabolic syndrome among
postmenopausal women. The study of Deibert et al. [46]
showed that prevalence of metabolic syndrome among
postmenopausal women was 36.1% and also some other
studies showed that menopausal women in Canada [47],
Ecuador [20], and Republic of Korea [48] had prevalence of
metabolic syndrome, 31%, 41.5%, and 54.6%, respectively.
In conclusion, our results show that postmenopausal
status might be a predictor of metabolic syndrome in this
area. In this study, low HDL-cholesterol level and high
abdominal obesity are the most frequent characteristics in
comparison to other metabolic components. Our study also
showed some related factors of metabolic syndrome among
postmenopausal women. These factors may increase car-
diovascular risk in postmenopausal women with metabolic
syndrome.
Authors’ Contribution
A. Marjani gave the idea, designed the study and wrote the
final paper. S. Moghasemi is co-author and was responsible
for the management of the patients and collection of medical
assessment findings.
Conflict of Interests
The authors have no conflicts of interests.
Acknowledgment
The study was funded by research deputy of Golestan Uni-
versity of Medical Sciences.
References
[1] P. J. Miranda, R. A. DeFronzo, R. M. Caliﬀ, and J. R. Guy-
ton, “Metabolic syndrome: definition, pathophysiology, and
mechanisms,” American Heart Journal, vol. 149, no. 1, pp. 33–
45, 2005.
[2] J. I. Cleeman, “Executive summary of the third report of
the National Cholesterol Education Program (NCEP) expert
panel on detection, evaluation, and treatment of high blood
cholesterol in adults (adult treatment panel III),” Journal of the
American Medical Association, vol. 285, no. 19, pp. 2486–2497,
2001.
[3] X. Ruan, J. Jin, L. Hua, Y. Liu, J. Wang, and S. Liu, “The
prevalence of metabolic syndrome in chinese postmenopausal
women and the optimum body composition indices to predict
it,” Menopause, vol. 17, no. 3, pp. 566–570, 2010.
[4] P. Shefali, M. Srinivas, S. Aghashe et al., “Menopause and
metabolic syndrome: a study of 498 urban women from
western India,” Journal of Mid-Life, no. 2, pp. 63–69, 2010.
[5] J. A. D. F. Neto, E. D. Figuereˆdo, J. B. Barbosa et al., “Metabolic
syndrome and menopause: cross-sectional study in gynecol-
ogy clinic,” Arquivos Brasileiros de Cardiologia, vol. 95, no. 3,
pp. 339–345, 2010.
[6] A. J. Cameron, J. E. Shaw, and P. Z. Zimmet, “The metabolic
syndrome: prevalence in worldwide populations,” Endocrinol-
ogy and Metabolism Clinics of North America, vol. 33, no. 2, pp.
351–375, 2004.
[7] D. Lloyd-Jones, R. Adams, M. Carnethon et al., “Heart
disease and stroke statistics—2009 update. A report from the
American heart association statistics committee and stroke
statistics subcommittee,” Circulation, vol. 119, no. 3, pp. 480–
486, 2009.
[8] D. J. Lerner and W. B. Kannel, “Patterns of coronary heart
disease morbidity and mortality in the sexes: a 26-year follow-
up of the Framingham population,” American Heart Journal,
vol. 111, no. 2, pp. 383–390, 1986.
[9] E. S. Ford, W. H. Giles, and W. H. Dietz, “Prevalence of the
metabolic syndrome among US adults: findings from the
Third National Health and Nutrition Examination Survey,”
Journal of the American Medical Association, vol. 287, no. 3,
pp. 356–359, 2002.
International Journal of Endocrinology 5
[10] W. Rosamond, K. Flegal, G. Friday et al., “Heart disease and
stroke statistics—2007 Update: a report from the American
Heart Association Statistics Committee and Stroke Statistics
Subcommittee,” Circulation, vol. 115, no. 5, pp. e69–e171,
2007.
[11] P. Chedraui, L. Hidalgo, D. Chavez, N. Morocho, M. Alvarado,
and A. Huc, “Quality of life among postmenopausal Ecuado-
rian women participating in a metabolic syndrome screening
program,” Maturitas, vol. 56, no. 1, pp. 45–53, 2007.
[12] Q. F. Ding, T. Hayashi, X. J. Zhang et al., “Risks of CHD
identified by diﬀerent criteria of metabolic syndrome and
related changes of adipocytokines in elderly postmenopausal
women,” Journal of Diabetes and its Complications, vol. 21, no.
5, pp. 315–319, 2007.
[13] A. Ponholzer, C. Temml, M. Rauchenwald, M. Marszalek, and
S. Madersbacher, “Is the metabolic syndrome a risk factor
for female sexual dysfunction in sexually active women?”
International Journal of Impotence Research, vol. 20, no. 1, pp.
100–104, 2008.
[14] R. Rossi, A. Nuzzo, G. Origliani, and M. G. Modena, “Met-
abolic syndrome aﬀects cardiovascular risk profile and re-
sponse to treatment in hypertensive postmenopausal women,”
Hypertension, vol. 52, no. 5, pp. 865–875, 2008.
[15] H. W. Peters, I. C. D. Westendorp, A. E. Hak et al., “Men-
opausal status and risk factors for cardiovascular disease,”
Journal of Internal Medicine, vol. 246, no. 6, pp. 521–528, 1999.
[16] W. B. Kannel, M. C. Hjortland, P. McNamara, and T.
Gordon, “Menopause and risk of cardiovascular disease. The
Framingham study,” Annals of Internal Medicine, vol. 85, no. 4,
pp. 447–452, 1976.
[17] G. Razay, K. W. Heaton, and C. H. Bolton, “Coronary heart
disease risk factors in relation to the menopause,” Quarterly
Journal of Medicine, vol. 85, no. 307-308, pp. 889–896, 1992.
[18] M. C. Hjortland, P. M. McNamara, and W. B. Kannel, “Some
atherogenic concomitants of menopause: the Framingham
study,” American Journal of Epidemiology, vol. 103, no. 3, pp.
304–311, 1976.
[19] M. Royer, C. Castelo-Branco, J. E. Blu¨mel et al., “The US
National Cholesterol Education Programme Adult Treatment
Panel III (NCEP ATP III): Prevalence of the metabolic
syndrome in postmenopausal Latin American women,” Cli-
macteric, vol. 10, no. 2, pp. 164–170, 2007.
[20] L. A. Hidalgo, P. A. Chedraui, N. Morocho, M. Alvarado, D.
Chavez, and A. Huc, “The metabolic syndrome among post-
menopausal women in Ecuador,” Gynecological Endocrinology,
vol. 22, no. 8, pp. 447–454, 2006.
[21] O. Lindquist, “Intraindividual changes of blood pressure,
serum lipids, and body weight in relation to menstrual status:
results from a prospective population study of women in
Goteborg, Sweden,” Preventive Medicine, vol. 11, no. 2, pp.
162–172, 1982.
[22] C. Bonithon-Kopp, P. Y. Scarabin, B. Darne, A. Malmejac,
and L. Guize, “Menopause-related changes in lipoproteins and
some other cardiovascular risk factors,” International Journal
of Epidemiology, vol. 19, no. 1, pp. 42–48, 1990.
[23] J. Jensen, L. Nilas, and C. Christiansen, “Influence of men-
opause on serum lipids and lipoproteins,” Maturitas, vol. 12,
no. 4, pp. 321–331, 1990.
[24] F. Azizi, P. Salehi, A. Etemadi, and S. Zahedi-Asl, “Prevalence
of metabolic syndrome in an urban population: Tehran Lipid
and Glucose Study,” Diabetes Research and Clinical Practice,
vol. 61, no. 1, pp. 29–37, 2003.
[25] N. Sarrafzadegan, R. Kelishadi, A. Baghaei et al., “Metabolic
syndrome: an emerging public health problem in Iranian
Women: Isfahan Healthy Heart Program,” International Jour-
nal of Cardiology, vol. 131, no. 1, pp. 90–96, 2008.
[26] World Health Organization, Prevention and Management of
the Global Epidemic of Obesity. Report of the WHO Consultation
on Obesity, Technical Report Series, No. 894, WHO, Geneva,
Switzerland, 1998.
[27] M. Dalton, A. J. Cameron, P. Z. Zimmet et al., “Waist cir-
cumference, waist-hip ratio and body mass index and their
correlation with cardiovascular disease risk factors in Aus-
tralian adults,” Journal of Internal Medicine, vol. 254, no. 6, pp.
555–563, 2003.
[28] C. Bengtsson and O. Lindquist, “Menopausal eﬀects on risk
factors for ischaemic heart disease,” Maturitas, vol. 1, no. 3,
pp. 165–170, 1979.
[29] T. W. Meade, A. P. Haines, and J. D. Imeson, “Menopausal
status and haemostatic variables,” Lancet, vol. 1, no. 8314, pp.
22–24, 1983.
[30] N. S. Weiss, “Relationship of menopause to serum cholesterol
and arterial blood pressure: the United States’health examina-
tion survey of adults,” American Journal of Epidemiology, vol.
96, no. 4, pp. 237–241, 1972.
[31] C. E. Davis, A. Pajak, S. Rywik et al., “Natural menopause
and cardiovascular disease risk factors: The Poland and US
collaborative study on cardiovascular disease epidemiology,”
Annals of Epidemiology, vol. 4, no. 6, pp. 445–448, 1994.
[32] E. Casiglia, D. D’Este, G. Ginocchio et al., “Lack of influence of
menopause on blood pressure and cardiovascular risk profile:
a 16-year longitudinal study concerning a cohort of 568 wom-
en,” Journal of Hypertension, vol. 14, no. 6, pp. 729–736, 1996.
[33] M. F. Reardon, P. J. Nestel, I. H. Craig, and R. W. Harper,
“Lipoprotein predictors of the severity of coronary artery
disease in men and women,” Circulation, vol. 71, no. 5, pp.
881–888, 1985.
[34] S. Bergman, G. Siegert, V. Wahrburg et al., “Influence of
menopause and life style factors on high-density lipoproteins
in middle aged women,” Journal of North American Menopause
Society, no. 4, pp. 52–61, 1997.
[35] K. A. Do, A. Green, J. R. Guthrie, E. C. Dudley, H. G. Burger,
and L. Dennerstein, “Longitudinal study of risk factors for
coronary heart disease across the menopausal transition,”
American Journal of Epidemiology, vol. 151, no. 6, pp. 584–593,
2000.
[36] K. A. Matthews, E. Meilahn, L. H. Kuller, S. F. Kelsey, A. W.
Caggiula, and R. R. Wing, “Menopause and risk factors for
coronary heart disease,” New England Journal of Medicine, vol.
321, no. 10, pp. 641–646, 1989.
[37] P. L. Torng, T. C. Su, F. C. Sung et al., “Eﬀects of menopause
and obesity on lipid profiles in middle-aged Taiwanese wom-
en: the Chin-Shan Community Cardiovascular Cohort Study,”
Atherosclerosis, vol. 153, no. 2, pp. 413–421, 2000.
[38] P. L. Torng, T. C. Su, F. C. Sung et al., “Eﬀects of menopause
on intraindividual changes in serum lipids, blood pressure,
and body weight—the Chin-Shan community cardiovascular
cohort study,” Atherosclerosis, vol. 161, no. 2, pp. 409–415,
2002.
[39] F. Azizi and E. Ainy, “Coronary heart disease risk factors and
menopause: a study in 1980 Tehranian women, the Tehran
Lipid and Glucose Study,” Climacteric, vol. 6, no. 4, pp. 330–
336, 2003.
[40] C. J. Kim, T. H. Kim, W. S. Ryu, and U. H. Ryoo, “Influence
of menopause on high density lipoprotein-cholesterol and
lipids,” Journal of Korean Medical Science, vol. 15, no. 4, pp.
380–386, 2000.
6 International Journal of Endocrinology
[41] R. A. Kreisberg and S. Kasim, “Cholesterol metabolism and
aging,” The American Journal of Medicine, vol. 82, no. 1, pp.
54–60, 1987.
[42] C. Walton, I. F. Godsland, A. J. Proudler, V. Wynn, and
J. C. Stevenson, “The eﬀects of the menopause on insulin
sensitivity, secretion and elimination in non-obese, healthy
women,” European Journal of Clinical Investigation, vol. 23, no.
8, pp. 466–473, 1993.
[43] R. A. Lobo, “Metabolic syndrome after menopause and the
role of hormones,” Maturitas, vol. 60, no. 1, pp. 10–18, 2008.
[44] R. Heidari, M. Sadeghi, M. Talaei, K. Rabiei, N. Moham-
madifard, and N. Sarrafzadegan, “Metabolic syndrome in
menopausal transition: Isfahan Healthy Heart Program, a
population based study,” Diabetology and Metabolic Syndrome,
vol. 2, no. 1, article no. 59, 2010.
[45] A. Ponholzer, C. Temml, M. Rauchenwald, M. Marszalek, and
S. Madersbacher, “Is the metabolic syndrome a risk factor
for female sexual dysfunction in sexually active women?”
International Journal of Impotence Research, vol. 20, no. 1, pp.
100–104, 2008.
[46] P. Deibert, D. Ko¨nig, M. Z. Vitolins et al., “Eﬀect of a weight
loss intervention on anthropometric measures and metabolic
risk factors in pre- versus postmenopausal women,” Nutrition
Journal, vol. 6, article no. 31, 2007.
[47] M. E`. Piche´, S. J. Weisnagel, L. Corneau, A. Nadeau, J. Ber-
geron, and S. Lemieux, “The WHO and NCEP/ATPIII def-
initions of the metabolic syndrome in postmenopausal
women: are they so diﬀerent?” Metabolic Syndrome and Re-
lated Disorders, vol. 4, no. 1, pp. 17–27, 2006.
[48] M. K. Hee, J. Park, Y. R. So, and K. I. M. Jongoh, “The
eﬀect of menopause on the metabolic syndrome among
Korean wwomen: the Korean National Health and Nutrition
Examination Survey, 2001,” Diabetes Care, vol. 30, no. 3, pp.
701–706, 2007.
Submit your manuscripts at
http://www.hindawi.com
Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
MEDIATORS
INFLAMMATION
of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Behavioural 
Neurology
Endocrinology
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Disease Markers
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Oncology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Oxidative Medicine and 
Cellular Longevity
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
PPAR Research
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Immunology Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Journal of
Obesity
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
